Embed Size (px)
Citation preview
Mario Thomas, Ph.D.
President
The Face of Oral Cancer
Kills 1 person/hour in North America
50% Mortality Rate within 5 years
Survivors = Poor quality of life
ROGER EBERT 1942-2013
The Problem: Late DetectionVisual assessment methods of precancerous lesions
unchanged in the last 100 years
1910 2014
More than 50% of high-risk lesions are missed!
3. Report Tool for clinicians to decide on
personalized treatment:
Detecting Cancer BEFORE it happenswith 90% Predictive Value
The Solution: Straticyte™ Test
2. Score Accurately measures individual probability
of cancer within the next 5 years
1. Test Patent-protected biomarkers to objectively
assess risk of pre-cancerous oral lesions
65%
STRATICYTE: HUGE Opportunity
3.3 million oral lesions
$990 Million
($300 /test)
2020 Sales Forecast $102 Million
Potential ROI 15x+Based on 5x projected EBITDA in 2020
Sustainable Competitive Advantage
Only competitor is the Standard Visual Method
Biomarkers and methods patented
6 patent families filed
7 issued patents in 2 families (Core US patent issued)
Trade Secrets: Reference database
Algorithm
Image acquisition
Go to Market StrategyCustomersChannels
Direct sales in North-America
Strategic Partners in other countries
Oral Surgeons
Oral Pathologists
Business Model
$ FEE
8
Oral Surgeon Oral Pathology Lab
Patient
Biopsy Biopsy
Results Biopsy
ResultsResults
$ FEE
Billable
Scalable
Profitable
Success Factors and Traction Traction Milestones
Product V.1.0Validated clinical
V2.0 Expanded clinical
Marketing Market Research done
Local Advisory Board
Health Economics
International Advisory Board
Sales Ontario Test MarketExceptional need
Canadian Roll-Out US launch
People Full time Management Sales ManagerProduct development ass.
Funding $ 750k committed $3 Million
2014 2015 2016
Automated test
Ontario Market Test
$1.0M financing
European Partner$1.0M financing
Roadmap to market –Risk Mitigation
Economic Study
Canada Roll-OutUSA pilot Site
Asian Partner
$0.75M financing
Target Company Acquirer Date Value ($mm)
Revenue Multiple
BioFire Molecular Dx BioMerieux Sept 2013 $450 6x
GenturaDx Molecular Dx Luminex July 2012 $50 Pre-revenue
Cellestis Molecular Dx Qiagen NV April 2011 $335 8.4X
Athena Dx Molecular Dx Quest Feb 2011 $700 7.0X
Clarient Cancer Dx GE Medical Oct 2010 $580 7.0X
Exit Strategy: Targeting15x ROI at year 5
Experienced Management with International Reach
Dr. Mario Thomas, PhD, DSA, C.Dir. President
Dr. Kenneth Pritzker, MD, FRCPC
CEO
Extensive experience in novel medical diagnostics. Former Head of Pathology at Mount-Sinai Hospital
Dr. Ranju Ralhan, PhD, FNAMS, Chief Scientific OfficerCIHR Rx&D Chair in Advanced Cancer Diagnostics, Professor, Department of Otolaryngology, University of Toronto
John Jordan, MBA, CPA, CMAChief Financial OfficerExperience in building technology companies
Key Hire Sales ManagerWill expand Canadian launch plan in Q1 2015
Scientific and Clinical AdvisorsMichael Siu PhD, F.R.S.C. VP Research, University of Windsor Chair, Ontario Cancer Biomarker Network Chair, Canadian National Proteomics Network
David Mock DDS, PhD, FRCD(C) Retired Professor, oral pathology Former Dean, Faculty of Dentistry, University of Toronto
Ian Witterick MD, MSC, FRCSC Professor and Chair, Department of Otolaryngology
and Head & Neck Surgery, University of Toronto.
Barrie Renick DDS, OMFS, dip. Oral path., dip. Oral surg., M.R.D.C. (C) Oral Maxillofacial Surgeon with extensive clinical practice
New Market, Ontario
